These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34203446)

  • 1. Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression.
    Kang EY; Kang C; Wu WC; Sun CC; Chen KJ; Lai CC; Chen TH; Hwang YS
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34203446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
    Chung YR; Ha KH; Kim HC; Park SJ; Lee K; Kim DJ
    Diabetes Metab J; 2019 Oct; 43(5):640-648. PubMed ID: 30877707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy.
    Kang EY; Chen TH; Garg SJ; Sun CC; Kang JH; Wu WC; Hung MJ; Lai CC; Cherng WJ; Hwang YS
    JAMA Ophthalmol; 2019 Apr; 137(4):363-371. PubMed ID: 30629109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
    Chung YR; Ha KH; Lee K; Kim DJ
    PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
    Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT
    Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
    Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS
    Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19.
    Zhou JH; Wu B; Wang WX; Lei F; Cheng X; Qin JJ; Cai JJ; Zhang XJ; Zhou F; Liu YM; Li HM; Zhu LH; She ZG; Zhang X; Yang J; Li HL
    World J Clin Cases; 2020 Nov; 8(22):5576-5588. PubMed ID: 33344548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Seong JM; Yee J; Gwak HS
    Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study.
    Lin YH; Huang YY; Wu YL; Lin CW; Chen PC; Chang CJ; Hsieh SH; Sun JH; Chen ST; Lin CH
    Diabetol Metab Syndr; 2018; 10():75. PubMed ID: 30349614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes.
    Chao CT; Wang J; Wu HY; Chien KL; Hung KY
    Oncotarget; 2017 Aug; 8(32):53028-53040. PubMed ID: 28881791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study.
    Chen HH; Hsieh MC; Ho CW; Chen CC; Hsu SP; Lin CL; Kao CH
    Ann Palliat Med; 2020 Sep; 9(5):2817-2825. PubMed ID: 32787376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults.
    Wang T; Hong JL; Gower EW; Pate V; Garg S; Buse JB; Stürmer T
    Diabetes Care; 2018 Sep; 41(9):1998-2009. PubMed ID: 30012674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study.
    Kim NH; Choi J; Kim NH; Choi KM; Baik SH; Lee J; Kim SG
    Diabetes Metab; 2018 Sep; 44(4):361-367. PubMed ID: 29752167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.